Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: May 12, 2025
Principal Executive Office: Marseille, France
Context: This filing serves as a conduit for a press release dated May 12, 2025 (Exhibit 99.1). The document itself contains no operational or financial data, only the cover page and signature block.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. No financial tables or numerical data are included in the provided content.
Material Changes
No material changes versus the prior comparable period can be identified from this document. The text contains no comparative financial data or operational updates.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are presumably contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Investor Verification Checklist
- Verify the specific content of the Press Release dated May 12, 2025 (Exhibit 99.1) referenced in this filing.
- Confirm whether the press release contains material non-public information regarding clinical trials, partnerships, or financial results.
- Review the company's most recent Form 20-F for the latest audited financial statements, as this 6-K contains none.